Hematopoietic cell transplantation, leukemia immunotherapy
Jean-Sébastien Delisle, MD, FRCPC, PhD
After completing his medical degree and clinical training in internal medicine and hematology within the McGill university hospital system, Dr Delisle received further training in allogeneic hematopoietic cell transplantation (AHCT) at Maisonneuve-Rosemont Hospital. He also obtained a PhD in Biomedical sciences from the University of Montréal after studying the regulation of hematopoietic cells by the cytokines Interferon-gamma and Transforming growth factor-beta (TGF-β) in pre-clinical models of AHCT. Since October 2010, he leads his own research group at the Maisonneuve-Rosemont Hospital Research Center (CR-HMR). Dr Delisle is an assistant-professor at the University of Montréal and holds an FRQS clinician-scientist career award.
Dr Delisle’s research program is composed of two axes. The first is devoted to T-cell biology and leukemia immunotherapy. More specifically, Dr Delisle investigates the role of the cytokine TGF-β in immune cell physiology and cancer immunology using both primary human cell cultures and pre-clinical animal models. A substantial part of his work aims at better defining how immunosuppressive TGF-β signaling impedes leukemia immunotherapy. The second axis is highly translational and aims to implement a human T-cell adoptive immunotherapy program at Hôpital Maisonneuve-Rosemont to treat blood neoplasms and virus-related complications following AHCT.